Alerts
Lung Cancer May Be Entering the Chemo-Replacement Fight
Phase III data reported in The Lancet and highlighted this week show sacituzumab tirumotecan plus pembrolizumab improved progression-free survival versus pembrolizumab alone in PD-L1-positive advanced NSCLC. The ADC era is moving into first-line lung cancer, but toxicity and sequencing will decide how far it goes.
MenB Vaccination Moves From Baby Schedule to Student Outbreak Control
Sanofi’s Tzield moves type 1 diabetes into disease modification, but access may decide who benefits
AML’s Frontline Future Starts With Finding the Mutation Fast
FSHD Gets a Stronger Biological Signal
Measles Deaths in England Expose the Cost of Missed Protection
Pancreatic Cancer Finally Gets a RAS Moment
A Rare Pain Disorder Gets a Pivotal Trial
Soft-Cheese Listeria Outbreak Shows Food Safety Is Patient Safety
GSK’s Nuvalent Deal Turns Lung Cancer Precision Into a $10.6 Billion Access Race
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.